Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1991 Oct 1;145(7):817–819.

Neuroleptic malignant syndrome without the use of neuroleptics.

D Heyland 1, M Sauvé 1
PMCID: PMC1335901  PMID: 1913410

Full text

PDF
817

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brennan D., MacManus M., Howe J., McLoughlin J. 'Neuroleptic malignant syndrome' without neuroleptics. Br J Psychiatry. 1988 Apr;152:578–579. doi: 10.1192/bjp.152.4.578b. [DOI] [PubMed] [Google Scholar]
  2. Caroff S. N. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980 Mar;41(3):79–83. [PubMed] [Google Scholar]
  3. Guzé B. H., Baxter L. R., Jr Current concepts. Neuroleptic malignant syndrome. N Engl J Med. 1985 Jul 18;313(3):163–166. doi: 10.1056/NEJM198507183130306. [DOI] [PubMed] [Google Scholar]
  4. Heffron J. J. Malignant hyperthermia: biochemical aspects of the acute episode. Br J Anaesth. 1988 Feb;60(3):274–278. doi: 10.1093/bja/60.3.274. [DOI] [PubMed] [Google Scholar]
  5. Holman R. B., Seagraves E., Elliott G. R., Barchas J. D. Stereotyped hyperactivity in rats treated with tranylcypromine and specific inhibitors of 5-HT reuptake. Behav Biol. 1976 Apr;16(4):507–514. doi: 10.1016/s0091-6773(76)91683-7. [DOI] [PubMed] [Google Scholar]
  6. Insel T. R., Roy B. F., Cohen R. M., Murphy D. L. Possible development of the serotonin syndrome in man. Am J Psychiatry. 1982 Jul;139(7):954–955. doi: 10.1176/ajp.139.7.954. [DOI] [PubMed] [Google Scholar]
  7. Kellam A. M. The neuroleptic malignant syndrome, so-called. A survey of the world literature. Br J Psychiatry. 1987 Jun;150:752–759. doi: 10.1192/bjp.150.6.752. [DOI] [PubMed] [Google Scholar]
  8. Kline S. S., Mauro L. S., Scala-Barnett D. M., Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm. 1989 Jul;8(7):510–514. [PubMed] [Google Scholar]
  9. Lader M. The problems of safety and compliance with conventional antidepressant drugs. Acta Psychiatr Scand Suppl. 1983;308:91–95. [PubMed] [Google Scholar]
  10. Linden C. H., Rumack B. H., Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med. 1984 Dec;13(12):1137–1144. doi: 10.1016/s0196-0644(84)80339-x. [DOI] [PubMed] [Google Scholar]
  11. Maguire J., Singh A. N. Clonidine. An effective anti-manic agent? Br J Psychiatry. 1987 Jun;150:863–864. doi: 10.1192/bjp.150.6.863. [DOI] [PubMed] [Google Scholar]
  12. Marley E., Wozniak K. M. Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine. J Psychiatr Res. 1985;19(4):597–608. doi: 10.1016/0022-3956(85)90079-2. [DOI] [PubMed] [Google Scholar]
  13. Rosebush P., Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry. 1989 Jun;146(6):717–725. doi: 10.1176/ajp.146.6.717. [DOI] [PubMed] [Google Scholar]
  14. Staufenberg E. F., Tantam D. Malignant hyperpyrexia syndrome in combined treatment. Br J Psychiatry. 1989 Apr;154:577–578. doi: 10.1192/bjp.154.4.577. [DOI] [PubMed] [Google Scholar]
  15. White K., Simpson G. The combined use of MAOIs and tricyclics. J Clin Psychiatry. 1984 Jul;45(7 Pt 2):67–69. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES